Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.2% – What’s Next?

Shares of Eli Lilly and Company (NYSE:LLY) dropped 1.2% during mid-day trading on Thursday . The stock traded as low as $1,171.71 and last traded at $1,175.0120. Approximately 2,624,870 shares traded hands during mid-day trading, a decline of 15% from the average daily volume of 3,087,471 shares. The stock had previously closed at $1,189.41.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.S. FDA approved Mounjaro (tirzepatide) to reduce the risk of cardiovascular death, nonfatal heart attack and nonfatal stroke in high-risk adults with Type 2 diabetes. The expanded label gives Lilly access to a broader diabetes and cardiovascular market and strengthens Mounjaro’s competitive position. US FDA approves Lilly’s Mounjaro to reduce cardiovascular risk
• Positive Sentiment: The approval is supported by clinical data showing Mounjaro produced an 8% lower rate of major cardiovascular events than Lilly’s Trulicity, potentially making the drug more attractive to physicians, patients and payers. Mounjaro versus Trulicity
• Positive Sentiment: The decision expands the commercial opportunity for Lilly’s approximately $9.94 billion Mounjaro franchise beyond blood-sugar control and weight loss, potentially supporting long-term revenue growth. Lilly’s Mounjaro franchise wins a heart-risk label
• Positive Sentiment: Lilly’s oncology business and pipeline are providing additional diversification, with oncology revenue reportedly rising 11% in the first half of 2026. Can Lilly’s oncology portfolio drive growth beyond GLP-1 drugs?
• Neutral Sentiment: Employer coverage for GLP-1 weight-loss medicines reportedly fell from 72% to 60%, raising concerns about affordability and future demand. However, Lilly’s recent 47% revenue growth suggests volume remains resilient despite payer pressure. GLP-1 coverage and Lilly’s weight-loss boom
• Negative Sentiment: LLY has pulled back after reaching a record high, while healthcare stocks broadly declined. Profit-taking and the stock’s elevated valuation may be limiting the immediate reaction to the positive Mounjaro news. Eli Lilly stock pulls back after hitting record high

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Berenberg Bank increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research note on Monday, June 22nd. Bank of America lifted their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Wolfe Research reiterated an “outperform” rating and set a $1,350.00 target price on shares of Eli Lilly and Company in a report on Thursday, May 21st. Cantor Fitzgerald increased their price target on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, UBS Group set a $1,376.00 price target on Eli Lilly and Company in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,292.18.

Eli Lilly and Company Trading Down 0.6%

The business’s 50 day simple moving average is $1,189.22 and its 200 day simple moving average is $1,065.30. The stock has a market cap of $1.10 trillion, a price-to-earnings ratio of 39.23, a PEG ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the business earned $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 23.22%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Cornerstone Financial Management LLC boosted its stake in Eli Lilly and Company by 18.7% in the 2nd quarter. Cornerstone Financial Management LLC now owns 356 shares of the company’s stock valued at $427,000 after purchasing an additional 56 shares during the period. Formuepleje A S bought a new position in Eli Lilly and Company during the 2nd quarter worth $5,569,000. Tucker Asset Management LLC raised its holdings in Eli Lilly and Company by 4.1% in the 2nd quarter. Tucker Asset Management LLC now owns 252 shares of the company’s stock valued at $302,000 after acquiring an additional 10 shares in the last quarter. HORAN Wealth LLC lifted its position in shares of Eli Lilly and Company by 7.3% during the 2nd quarter. HORAN Wealth LLC now owns 884 shares of the company’s stock valued at $1,060,000 after acquiring an additional 60 shares during the period. Finally, Principia Wealth Advisory LLC grew its holdings in shares of Eli Lilly and Company by 12.8% during the 2nd quarter. Principia Wealth Advisory LLC now owns 167 shares of the company’s stock worth $200,000 after purchasing an additional 19 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.